CYBN) surged as much as 10% on Monday, reaching their highest level since May, following the announcement of “unprecedented” ...

This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown potential as a treatment for major depressive disorder (MDD), and other severe ...

Most people want less anxiety. The goal is to actually have realistic anxiety levels. Here, I explain how to attain realistic ...

Dual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist demonstrates enhanced efficacy in preclinical ...

Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative ...

(SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe stress-related conditions ... severe ...

Cybin has reported 71% remission in patients with major depressive disorder (MDD) who received two doses of the ... that are ...

On a sunny day in July, while other Bay Area kids were playing at camps or water parks, 8-year-old Charlotte O’Neill was leaning back in a reclining chair in a small, carpeted San Jose office room.

Greenbrook TMS Inc. ("Greenbrook" or the "Company") is pleased to announce that the Company has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...